By Blessing Nweke
Novo Nordisk has filed a lawsuit against rival pharmaceutical company Eli Lilly, accusing it of using misleading advertisements to promote its popular weight-loss and diabetes medications. The legal action marks the latest escalation in a fierce competition between the two companies for dominance in the rapidly growing obesity drug market.
The Danish drugmaker, which produces Wegovy and Ozempic, filed the complaint in a U.S. federal court in New Jersey. Novo alleges that Lilly violated false advertising and unfair competition laws by running campaigns that compare its drugs, Zepbound and Mounjaro, with Novo’s treatments using outdated clinical trial information.
Novo claims Lilly’s advertisements present an unfair comparison by highlighting weight-loss results from higher doses of Lilly’s medicines against lower doses of Novo’s drugs, while failing to include newer data involving updated versions of Novo’s treatments. The company is seeking a court order requiring Lilly to remove the advertisements, issue corrective messaging and pay damages.
The dispute comes as demand for GLP-1 medications, a class of drugs used to treat obesity and Type 2 diabetes, continues to surge. Both companies have invested heavily in expanding their share of the market, which has become one of the most competitive areas in the pharmaceutical industry.
Eli Lilly has defended its advertising, pointing to clinical research supporting its products and maintaining that its comparisons are based on scientific evidence. The company has argued that studies such as its SURMOUNT-5 trial support the effectiveness of Zepbound.
The lawsuit adds another chapter to the rivalry between Novo Nordisk and Eli Lilly, whose weight-loss drugs have become global blockbusters. The outcome could influence how pharmaceutical companies market obesity treatments and compare competing therapies to consumers.
Original article
Comments